In our cohort, all HER2 positive breast cancer patients had benefits from HER2 targeted therapy, and a higher expression of HER2, EGFR, PTEN and HER3 but lower expression of phospho-HER2 correlated with trastuzumab sensitivity. This evidence concerns the gene ERBB2 and breast carcinoma.